'Trusted' NHS must bring R&D benefits to the disadvantaged

Research

Realignment of R&D investment could generate a better return on R&D investment to UK plc by improving access to innovative medicines, reducing variations in health outcomes, reengaging people with the labour market, and improving healthy life expectancy, write Jonathan Pearson-Stuttard and James O’Shaughnessy.

Register with hsj.co.uk to read the rest of this article

HSJ

Critical stories remain free for registered users

Certain articles and Insight pieces remain paying-subscriber only content

As a registered user you will get access to:

  • Daily News: an essential email round-up of all the latest news, comment and best practice
  • Breaking news headlines delivered directly to your inbox
  • Limited access to hsj.co.uk

Already registered to HSJ? Sign in now